Rezolute, Inc. will release its fourth-quarter 2026 earnings after market close on Wednesday, Sept. 16, 2026. Analysts forecast a loss of $0.1479 per share for the period.
The announcement follows recent clinical updates, including an ongoing FDA review of data for the drug ersodetug. Rezolute also concludes its participation in the H.C. Wainwright and Morgan Stanley healthcare conferences on Sept. 16.
Management commentary will address the company's progress in clinical programs for rare and metabolic diseases. The report provides updated insights into the development pipeline and future financial outlook.